Literature DB >> 8996040

The hospital discharge decision for patients with community-acquired pneumonia. Results from the Pneumonia Patient Outcomes Research Team cohort study.

M J Fine, A R Medsger, R A Stone, T J Marrie, C M Coley, D E Singer, H Akkad, L J Hough, W Lang, E M Ricci, D M Polenik, W N Kapoor.   

Abstract

BACKGROUND: The hospital discharge decision directly influences the length of stay in patients with community-acquired pneumonia, yet no information exists on how physicians make this decision.
OBJECTIVES: To identify the factors physicians considered the factors responsible for extending length of hospital stay in clinically stable patients, and the outpatient medical services that would allow earlier hospital discharge for patients with community-acquired pneumonia.
METHODS: Physicians responsible for the hospital discharge decision of patients with community-acquired pneumonia were asked to identify the factors responsible for extending stay in patients hospitalized beyond stability, and the medical services that could have allowed earlier hospital discharge to occur.
RESULTS: For the 418 eligible patients with community-acquired pneumonia identified during the study, 332 questionnaires (79%) were completed by 168 physicians. Physicians believed 71 patients (22%) were discharged from the hospital 1 day or more (median, 2.5 days) after reaching clinical stability. The most common factors rated as being "very important" in delaying discharge were diagnostic evaluation or treatment of comorbid illness (56%), completion of a "standard course" of antimicrobials (15%), and delays with arrangements for long-term care (14%). Among the 302 patients with available information on both length of hospital stay and stability at discharge, median length of stay was 7.0 days for the 29 low-risk patients hospitalized beyond reaching clinical stability and 5.0 days for the remaining 128 low-risk patients (P < .005); median length of stay was 12.5 days for the 42 medium- and high-risk patients hospitalized beyond reaching clinical stability and 8.0 days in the remaining 113 medium- and high-risk patients (P < .001). Frequently cited medical services that "probably" or "definitely" would have allowed earlier discharge to occur included availability of home intravenous antimicrobial infusion (26%) and home visits by nurses (20%).
CONCLUSIONS: Physicians believed that diagnostic evaluation or treatment of comorbid illness, completion of a standard course of antimicrobial therapy, and delays with arrangements for long-term care delayed hospital discharge in clinically stable patients. Addressing the efficiency of these aspects of inpatient medical care, as well as providing home treatment programs, could decrease the length of hospital stay in patients with community-acquired pneumonia.

Entities:  

Mesh:

Year:  1997        PMID: 8996040

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  13 in total

1.  Treatment and outcomes of community-acquired pneumonia at Canadian hospitals.

Authors:  B G Feagan; T J Marrie; C Y Lau; S L Wheeler; C J Wong; M K Vandervoort
Journal:  CMAJ       Date:  2000-05-16       Impact factor: 8.262

2.  Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society.

Authors:  L A Mandell; T J Marrie; R F Grossman; A W Chow; R H Hyland
Journal:  Can J Infect Dis       Date:  2000-09

3.  Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study.

Authors:  M M van der Eerden; F Vlaspolder; C S de Graaff; T Groot; W Bronsveld; H M Jansen; W G Boersma
Journal:  Thorax       Date:  2005-08       Impact factor: 9.139

4.  New ways to look at old patterns? Sequence analysis to analyze patterns of clinical stability in community-acquired pneumonia.

Authors:  Marisha Burden; Eric M Mortensen
Journal:  J Gen Intern Med       Date:  2014-04       Impact factor: 5.128

5.  What factors influence physicians' decisions to switch from intravenous to oral antibiotics for community-acquired pneumonia?

Authors:  E A Halm; G E Switzer; B S Mittman; M B Walsh; C C Chang; M J Fine
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

Review 6.  Community-acquired pneumonia in the elderly: a practical guide to treatment.

Authors:  D Lieberman; D Lieberman
Journal:  Drugs Aging       Date:  2000-08       Impact factor: 3.923

7.  Sequence patterns in the resolution of clinical instabilities in community-acquired pneumonia and association with outcomes.

Authors:  Gavin W Hougham; Sandra A Ham; Gregory W Ruhnke; Elizabeth Schulwolf; Andrew D Auerbach; Jeffrey L Schnipper; Peter J Kaboli; Tosha B Wetterneck; David Gonzalez; Vineet M Arora; David O Meltzer
Journal:  J Gen Intern Med       Date:  2013-10-03       Impact factor: 5.128

8.  Cost-effectiveness of procalcitonin-guided antibiotic use in community acquired pneumonia.

Authors:  Kenneth J Smith; Angela Wateska; M Patricia Nowalk; Mahlon Raymund; Bruce Y Lee; Richard K Zimmerman; Michael J Fine
Journal:  J Gen Intern Med       Date:  2013-09       Impact factor: 5.128

9.  Does physicians' case volume impact inpatient care costs for pneumonia cases?

Authors:  Hsiu-Chen Lin; Sudha Xirasagar; Herng-Ching Lin; Yi-Ting Hwang
Journal:  J Gen Intern Med       Date:  2007-11-28       Impact factor: 5.128

10.  Outcomes of early switching from intravenous to oral antibiotics on medical wards.

Authors:  Dominik Mertz; Michael Koller; Patricia Haller; Markus L Lampert; Herbert Plagge; Balthasar Hug; Gian Koch; Manuel Battegay; Ursula Flückiger; Stefano Bassetti
Journal:  J Antimicrob Chemother       Date:  2009-04-28       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.